ALD and MLD to be Screened in Newborns in UK Generation Study
source: shutterstock.com

ALD and MLD to be Screened in Newborns in UK Generation Study

Patient Worthy partner Alex TLC has announced that, in a large-scale newborn screening study supported by the UK's NHS and Genomics England, adrenoleukodystrophy (ALD) and metachromatic leukodystrophy (MLD) will be…

Continue Reading ALD and MLD to be Screened in Newborns in UK Generation Study
Gene Therapy Saves Boy with ALD
source: pixabay.com

Gene Therapy Saves Boy with ALD

  Growing up, Priscilla Veneklause watched as her father struggled to manage his rare genetic disorder: adrenoleukodystrophy (ALD). Unfortunately, her father lost his fight with ALD when Priscilla was still…

Continue Reading Gene Therapy Saves Boy with ALD
Gene Therapy for Cerebral Adrenoleukodystrophy Earns FDA Accelerated Approval
source: shutterstock.com

Gene Therapy for Cerebral Adrenoleukodystrophy Earns FDA Accelerated Approval

According to a press release, the gene therapy company bluebird bio, inc. has recently announced that its gene therapy elivaldogene autotemcel (marketed as SKYSONA) has received Accelerated Approval status from…

Continue Reading Gene Therapy for Cerebral Adrenoleukodystrophy Earns FDA Accelerated Approval
FDA Halted Phase 3 Trial for Cerebral Adrenoleukodystrophy Due to Participant Developing MDS
source: pixabay.com

FDA Halted Phase 3 Trial for Cerebral Adrenoleukodystrophy Due to Participant Developing MDS

      Science Magazine recently joined other news sources in reporting that Bluebird Bio’s Phase 3 clinical trial investigating a treatment for a neurological disease was put on hold by…

Continue Reading FDA Halted Phase 3 Trial for Cerebral Adrenoleukodystrophy Due to Participant Developing MDS
VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
source: pixabay.com

VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat

In November 2020, Viking Therapeutics ("Viking") shared insight into their metabolic disease program. According to Greg Zante, the Senior VP (SVP) of Finance for Viking, the company's treatment VK2809, licensed…

Continue Reading VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders
source: pixabay.com

Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders

  According to an article in BioPortfolio, Magenta Therapeutics, a biotechnology company based in Cambridge, Mass., recently announced updates to its Phase II trial of MGTA-456 for the treatment of…

Continue Reading Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders
A New Pediatric Precision Medicine Center is Opening in Utah
source: pixabay.com

A New Pediatric Precision Medicine Center is Opening in Utah

A new precision medicine center, specifically for pediatrics, has launched in Utah. This new center is the result of collaborative efforts from the Intermountain Primary Children's Hospital, Intermountain Precision Genomics,…

Continue Reading A New Pediatric Precision Medicine Center is Opening in Utah
New Trial Data Bodes Well for Experimental Cerebral Adrenoleukodystrophy Gene Therapy
skeeze / Pixabay

New Trial Data Bodes Well for Experimental Cerebral Adrenoleukodystrophy Gene Therapy

According to a story from pmlive.com, the gene therapy company Bluebird Bio's latest recently released results from the company's phase 2/3 clinical trial demonstrates further encouraging data for its Lenti-D…

Continue Reading New Trial Data Bodes Well for Experimental Cerebral Adrenoleukodystrophy Gene Therapy
Results From a Study of Gene Therapy for Cerebral Adrenoleukodystrophy Appear Positive
mcmurryjulie / Pixabay

Results From a Study of Gene Therapy for Cerebral Adrenoleukodystrophy Appear Positive

According to a story from PharmaTimes, the gene therapy company Bluebird bio has released updated results from a clinical study of its Lenti-D gene therapy as a treatment for patients…

Continue Reading Results From a Study of Gene Therapy for Cerebral Adrenoleukodystrophy Appear Positive
ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
HeungSoon / Pixabay

ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial

According to a story from Ysios Capital, the biotechnology company Minoryx Therapeutics recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This trial…

Continue Reading ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial